Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Nicole Longo

Nicole Longo Nicole is senior director of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.

Recent Posts

CMS guidance on IRA price setting process doubles down on bad policy

By Nicole Longo  |    April 14, 2023
As part of the implementation of the Inflation Reduction Act (IRA), the Centers for Medicare & Medicaid Services (CMS) issued draft guidance on the process for setting the price of medicines. The...   Read More

A guide to MedPAC’s Part B vote today

By Nicole Longo  |    April 13, 2023
Today, the Medicare Payment Advisory Commission (MedPAC), an independent congressional agency that advises Congress on issues related to the Medicare program, will vote on draft recommendations...   Read More

MedPAC proposal threatens access to medicines in Part B

By Nicole Longo  |    April 6, 2023
Next week, the Medicare Payment Advisory Commission (MedPAC) will vote on a number of policy proposals for changing Medicare Part B. One of the proposals would recommend that Congress adjust the...   Read More

How Part B’s ASP system helps control costs for the government and seniors

By Nicole Longo  |    March 30, 2023
Between Congress, the Medicare Payment Advisory Commission (MedPAC) and the Center for Medicare & Medicaid Innovation (CMMI), there have been a number of policy proposals of late that would change...   Read More

Medicare Part B spending in four points

By Nicole Longo  |    March 28, 2023
It’s that time of year again when the president releases his budget and questions arise about the solvency of the Medicare trust fund and Medicare spending more generally. Too often, critics point to...   Read More

Why Congress should prioritize fixing the 340B program

By Nicole Longo  |    March 2, 2023
Nearly all Americans nationwide agree: Lowering out-of-pocket costs for health care should be a top priority for policymakers. Luckily, there are commonsense policies Congress could implement to...   Read More

WTAS: Inflation Reduction Act already impacting R&D decisions

By Nicole Longo  |    January 17, 2023
The Inflation Reduction Act’s (IRA’s) drug price setting provisions, as predicted, are already impacting biopharmaceutical research & development (R&D) decisions. Whether you are looking at estimates...   Read More

340B program continues to drive shift in care to more expensive hospital settings

By Nicole Longo  |    December 15, 2022
Yet another study highlights the unintended consequences of the 340B program, which is increasing costs for patients and the health care system as a whole. In this case, the Berkeley Research Group...   Read More

The 340B program is interfering with the U.S. biosimilars market and impacting patient costs

By Nicole Longo  |    November 21, 2022
Research has shown that 340B hospitals are more likely to prescribe more expensive medicines and significantly mark up the price of medicines. For example, 340B hospitals received nearly five times...   Read More

Medicare Part D open enrollment and what recent changes mean for beneficiaries

By Nicole Longo  |    November 17, 2022
It’s that time of year again: Medicare open enrollment! Seniors and people with disabilities who are newly eligible for Medicare, as well as current Medicare beneficiaries, can select or update their...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates